Horizon Therapeutics Public (Nasdaq: HZNP) – Horizon Therapeutics is a biopharmaceutical company based in Dublin, Ireland. The company was founded in 2005. The company focuses on developing and marketing medicines that treat rare and rheumatic diseases. The diseases that the company’s drugs treat at this time include gout, rheumatoid arthritis, and osteoarthritis.
Horizon has really strong management efficiency measurements with a return on equity of 30.6% and a profit margin of 29.4%.
The company did see a big jump in first quarter earnings—up 131% compared to the first quarter of 2018.
The company’s sales have been growing at a rate of 11% per year over the last three years and they jumped 25% in the first quarter compared to a year earlier.
The sentiment for Horizon isn’t terribly bearish, but it also isn’t terribly bullish.
There are only 10 analysts following the stock at this time and eight of them have the stock rated as a “buy”. The other two analysts have the stock rated as a “hold”. The short interest ratio is at 2.86 and that is an average reading.
The weekly chart is a big driver behind this recommendation. We see that the stock has been trending higher over the last few years and a trend line has formed that connects the lows from the past 15 months or so. The stock is sitting just above that trend line after hitting in each of the last few weeks. The weekly stochastic readings are right at oversold territory and look as if they are ready to start moving higher.
Suggested strategy: Buy HZNP with a maximum entry price of $25.50. I would set a target of at least $33.00 over the next 12 months. I would suggest a stop loss at the $20 level.
— Rick Pendergraft
Virginia Stock-Picking Millionaire Says It's Not About Diversification! One single stock under $5- that trades under a secret name- could help you build your retirement. His details are here.